1. Home
  2. THE CING
  3. Biomedical Sciences
  4. Molecular Genetics Thalassaemia Department
  5. Research
  6. Grants Obtained

Molecular Genetics Thalassaemia Department

Grants Obtained
  1. GenoMed4ALL (Genomics and Personalized Medicine for all though Artificial Intelligence in Haematological Diseases) – 101017549, 2021-2024. Funded by H2020-SC1-FA-DTS-2020-1 with the total amount of € 9,999,064. MGTD received € 330,250. Research coordinator: Dr Petros Kountouris.
  2. RADEEP (Rare Anaemia Disorders European Epidemiological Platform), 2021-2023. Funded by Novartis/Celgene. Research coordinator: Dr Petros Kountouris.
  3. Norway Grant CING (New infrastructure for diagnosis and treatment of patients), 2020-2023. Funded by Norwegian Financial Mechanism with the amount of      € 595,000. Research coordinators: Dr Carsten W. Lederer, Dr Leonidas Phylactou.
  4. ENROL (European Rare Blood Disorders Epidemiology Platform) – 947670, 2020-2022. Funded by HP-PJ-2019 with the total amount of € 199,371. MGTD received € 59,154. Research coordinator: Dr Petros Kountouris.
  5. RANGS (Investigation of the molecular basis of rare anaemias in Cyprus), January – December 2020. Funded by CING where MGTD received € 29,000. Research coordinator: Dr Thessalia Papasavva.
  6. HEPATOMICS (Identification of novel peripheral blood biomarkers for liver disease in β-thalassaemia patients through the use of ‘omics’ technologies) - EXCELLENCE/0918/0118, 2019-2021. Funded by RIF - Excellence Hubs with the amount total of € 250,000. MGTD received € 238,000. Research coordinator: Dr Marios Phylactides.
  7. βTHAL-GT4U (Personalized Gene Therapy for β-thalassaemia) - EXCELLENCE/1216/0092, 2019-2022. Funded by RIF - Excellence Hubs with the amount of € 250,000. Research coordinator: Dr Carsten W. Lederer.
  8. HAPLONID (Non-invasive diagnosis of β-globinopathies using targeted next generation sequencing haplotype analysis) - EXCELLENCE/1216/0484, 2019-2022. Funded by RIF - Excellence Hubs with the total amount of € 250,000. MGTD received € 244,000. Research coordinator: Dr Thessalia Papasavva.
  9. HAEMOMICS (Omic studies of the mechanism of activation of gamma-globin for the treatment of haemoglobinopathies) - EXCELLENCE/1216/0389, 2019-2022. Funded by RIF - Excellence Hubs with the total amount of  € 250,000. MGTD received € 245,200. Research coordinator: Dr Marios Phylactides.
  10. ITHANET (Expanding the international ITHANET community portal for haemoglobinopathies) - EXCELLENCE/1216/0256, 2019-2022. Funded by RIF - Excellence Hubs with the amount of € 250.000. Research coordinator: Dr Petros Kountouris.
  11. ARISE (African Research and Innovative Initiative for Sickle Cell Education) – 824021, 2019-2022. Funded by H2020-MSCA-RISE-2018 with the total amount of € 2,106,800. MGTD received € 225.400. Research coordinator: Dr Coralea Stephanou.
  12. ID-EPTRI (Infradev-European Paediatric Translation Research Infrastructure), 2018-2020. Funded by H2020-INFRADEV-01-2017 with the amount of € 3,000,000. MGTD received € 128,750. Research coordinator: Dr Marina Kleanthous.
  13. Innovating Delivery of Genome Editing Tools for Haemoglobinopathies, 2018-2021. Funded by TELETHON Cyprus with the amount of € 60,000. Research coordinator: Dr Carsten W. Lederer.
  14. Advanced Analyses of Factors Regulating Erythroid Differentiation and Hemoglobinization, 2017-2021. Funded by EuroBank Cyprus with the amount of € 60,000. Research coordinator: Dr Carsten W. Lederer.
  15. PKDeep, 2017-2018. Funded by the FUNDACIÓ INSTITUT RECERCA CONTRA LA LEUCÈMIA JOSEP CARRERAS with the amount of € 35,000. Research coordinator: Dr Petros Kountouris.
  16. HANGS (NGS-based genetic screening and diagnostic test for hereditary haemolytic anaemias and haemoglobinopathies), 2016-2019. Funded by RCB Bank with the total amount of €180,000. MGTD received € 22,500. Research coordinator: Dr Thessalia Papasavva.
  17. Non Invasive Prenatal Diagnosis of β-thalassaemia based on the detection of paternally inherited alleles using Targeted Next Generation Sequencing, 2015-2018. Funded by TELETHON Cyprus with the amount of € 60,000. Research coordinator: Dr Thessalia Papasavva.
  18. Genome editing by non-homologous end joining as high efficiency gene therapy for sickle-cell disease and β-thalassaemia, 2014-2017. Funded by TELETHON Cyprus with the amount of € 60,000. Research coordinator: Dr Carsten W. Lederer.
  19. eENERCA (New e-Health services for the European reference network on rare anaemias), 2013 – 2016, Funded by the Health Program 2008-2013 with the amount of € 2,056,875.
  20. EU-ROS, 2012-2016. Funded by the European COST program.
  21. THALAMOSS (THALAssaemia MOdular Stratification System for personalized therapy of beta-thalassemia)-306201, 2012 – 2016, Funded by FP7-HEALTH-2012-INNOVATION-1 with the total amount of € 6,730,513.08. MGTD received € 581,725. Research coordinator: Dr. Roberto Gambari.
  22. Advancing gene therapy vectors for thalassaemia-ΥΓΕΙΑ/ΒΙΟΣ/0311(ΒΕ)/20, 2012 – 2014. Funded by the RPF with the amount of € 139,979.2. Research coordinators: Dr Carsten W. Lederer, Dr Marina Kleanthous.
  23. Genotype / phenotype correlation studies for HbH disease patients and all β-thalassaemia patients in Cyprus-ΥΓΕΙΑ/ΒΙΟΣ/0311(ΒΙΕ)/39, 2012-2014. Funded by the RPF with the amount of € 180,000. Research coordinator: Dr Marios Phylactides.
  24. Screening and delineation of molecular mechanisms of action of novel agents for the treatment of β-thalassaemia, 2012-2014. Funded by the RPF with the amount of € 139,996. Research coordinator: Dr Marios Phylactides.
  25. Molecular Basis of Alpha-Thalassaemia among Qatari population, 2011 – 2013. Funded by the QNRF with the amount of $ 332,700.
  26. Chemoinformatics solutions for the identification and organization of agents for the treatment of thalassaemia, 2011 - 2013. Funded by RPF with the amount of € 180,000. Research

  27. ITHANET (The International Haemoglobinopathy Portal), 2008-2010. Funded by RPF with the amount of € 130,000. Research coordinators: Dr Carsten W. Lederer, Dr Marina Kleanthous.

  28. GEPHEHEM (Phenotype/Genotype correlation studies on haemoglobinopathies), 2008-2010. Funded by RPF with the amount of CYP 8,823.

  29. EUROGENE (The first Pan-European Learning Services in the Field of Genetics), 2007-2010. Funded by FP6 with the amount of € 1,657,650.

  1. HU-Pharmgk (Pharmacogenomic analysis of β-thalassaemia patients under Hydroxyurea treatment: Implications for β-thalassaemia therapeutics), 2007-2009. Funded by RPF with the amount of CYP 79,200.
  2. MedGenNet (Euro-Mediterranean Network for Genetic Services), 2007-2009. Funded by FP6 with the amount of € 749,177.
  3. ITHANET (eInfrastructure for Thalassaemia Research Network), 2006-2008. Funded by FP6 with the total amount of € 1,200,000. Research coordinator: Dr Marina Kleanthous.
  4. ΕΕΑΘΑ (Reactivation of HbF for thalassaemia treatment), 2005-2008. Funded by the RPF with the total amount of CYP 57,475.
  5. ENERCA II (European Network for Rare and Congenital Anaemias), 2005-2007. Funded by E.C. with the total amount of € 658,000.
  6. SAFE (Special Non-Invasive Advances in Foetal and Neonatal Evaluation Network), 2004-2008. Funded by E.C. with the total amount of € 12,000,000.
  7. EUMEDIS, 2002-2005. Funded by E.C. with the total amount of € 1,040,000.
  8. Phenotype/Genotype correlation in thalassaemia intermedia, 1998-2001. Funded by the International Atomic Energy Agency (IAEA) with the amount of US$ 16,000.
  9. Euro-Mediterranean Network for Genetic Services.

  10. Determination of unknown α-thal mutations in Cyprus, 1998-2001. Funded by the Pancyprian Antianemic Association with the amount of CYP 8,900.

  11. Prevention of Scrapie in Cyprus.  PrP Genotyping, 1998-2000. Funded by EU grant of the Veterinary Services with the amount of CYP 40,000.

  12. Diagnosis of genetic disorders using radionuclide-based molecular methods. Renewal 1998-1999. Funded by the International Atomic Energy Agency with the amount of US$ 5,000.

  13. Prevention of Scrapie in Cyprus.  PrP Genotyping, June 1997 - Dec 1997. Funded by the Veterinary Services with the amount of CYP 5,800.

Screening and delineation of molecular mechanisms of action of novel agents for the treatment of β-thalassaemia

Title:   Screening and delineation of molecular mechanisms of action of novel agents for the treatment of β-thalassaemia Funding body: Cyprus ...

Advancing Gene Therapy Vectors for Thalassaemia

Thalassaemia is a potentially lethal single-gene disorder endemic to Cyprus, with curative treatment options only for a small proportion of patients and with a ...

winner